PUL-042

Status
Phase 2
Condition
COVID-19
Intervention Type
Inhaled Drug
Funder Type
Industry

Drug Details

PUL-042 is a novel combination of two synthetic molecules (Pam2 and ODN) that are agonists of Toll-like receptors.

Study Details

Adults who have tested positive for SARS-CoV-2 infection and are under observation or admitted to a controlled facility (such as a hospital) will receive PUL-042 Inhalation Solution or placebo up to 3 times over a one week period in addition to their normal care. Subjects will be be followed and assessed for their clinical status over a 14 day period with follow up at 28 days to see if PUL-042 Inhalation Solution improves the clinical outcome

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >